Trends in analgesia‐sedation of pediatric patients receiving I‐131 MIBG in the pediatric intensive care unit: A report from the Pediatric Health Information System database

Abstract

BackgroundChildren with neuroblastoma receiving I‐131 metaiodobenzylguanidine (MIBG) therapy require sedation‐analgesia for strict radiation safety precautions during MIBG infusion and clearance. We evaluated the sedation‐analgesia trends of patients undergoing MIBG therapy using the Pediatric Health Information System (PHIS) database.Materials and methodsRetrospective data from 476 patient encounters from the PHIS from 2010 to 2019.ResultsTotal 240/476 (50.45%) children evaluated were under 6 years of age. Compared to 2010, in 2018 there was a decrease in benzodiazepine infusion use (60% vs. 40%, p < .04), as well as a decrease in use of opiate infusion (35% vs. 25%, p < .001). Compared to 2010, in 2018 we report an increase in the use of ketamine (from 5% to 10%, p < .002), as well as an increase in dexmedetomidine use (0% vs. 30%, p < .001). Dexmedetomidine was the most used medication in the 0–3 years age group compared to children older than 3 years of age (14.19% vs. 5.80%, p < .001). Opiate was the most used medication in children greater than 3 years compared to the 0–3‐year age group (36.23 vs. 23.87, p < .05).ConclusionUsing PHIS data, we discovered considerable variability in the medications used for sedation in patients undergoing MIBG therapy. Although benzodiazepines and opioids were the most used agents, there was a trend toward decreasing use of benzodiazepines and opioids in these patients. Furthermore, there has been an increasing trend in the use of dexmedetomidine and ketamine.